Last updated: 11/07/2018 09:31:27

Bupropion & Cardio Birth Defect (Slone)

GSK study ID
115433
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Finalized
Finalized
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: Bupropion and Cardiac Birth Defects (Slone Epidemiology Center)
Trial description: Bupropion is a unique drug that is used both to treat depression and as an aid in smoking cessation. In 2008, the final report from the Bupropion pregnancy registry described 24 congenital malformations among the 675 women exposed to bupropion in the first trimester of pregnancy. Of these, 9 had congenital heart disease of varying severity, including a number of infants with ventricular septal defects (VSDs); of note, 2 of these 9 had coarctation of the aorta. More recently, Alwan et al, in an analysis of data from the Centers for Disease Control and Prevention’s case-control National Birth Defects Prevention Study, reported an increased risk of left outflow tract heart defects, a subgroup of cardiac malformations that includes coarctation of the aorta and hypoplastic left heart syndrome.
Data from the Slone Epidemiology Center Birth Defects Study will be used to test these observations. The outcomes of primary interest will include those hypothesized to be associated with bupropion in recent studies: left outflow tract defects considered as a group. Coarctation of the aorta and hypoplastic left heart syndrome will also be examined separately. All infants with congenital heart defects are further classified into subgroups that are embryologically meaningful, including left outflow tract defects. In secondary analyses, other heart defect classes for which there are adequate numbers of cases will be evaluated.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:

Diagnosis of left outflow tract defects

Timeframe: Within 6 months of delivery

Diagnosis of coarctation of the aorta

Timeframe: Within 6 months of delivery

Diagnosis of hypoplastic left heart syndrome

Timeframe: Within 6 months of delivery

Secondary outcomes:

Diagnosis of other congenital heart defects

Timeframe: Within 6 months of delivery

Interventions:
Drug: Exposure to any bupropion during the first trimester
Drug: Exposure to bupropion alone during the first trimester
Other: Referent group: no exposure to any anti-depressant or anti-smoking drug during pregnancy
Enrollment:
1
Observational study model:
Case-Control
Primary completion date:
Not applicable
Time perspective:
Retrospective
Clinical publications:
Louik C, Kerr S, Mitchell AA.First-Trimester Exposure to Bupropion and Risk of Cardiac Malformations.Pharmacoepidemiol Drug Saf.2014;23(10):1066-1075
Medical condition
Depressive Disorder
Product
bupropion
Collaborators
Not applicable
Study date(s)
September 2011 to August 2012
Type
Observational
Phase
Not applicable

Participation criteria

Sex
Female & Male
Age
Not applicable
Accepts healthy volunteers
No
  • Subjects with congenital heart defects who are born within the catchment areas of the 4 study centers
  • A sample of nonmalformed infants born at participating hospitals
  • Infants with chromosomal anomalies

Trial location(s)

No location data available.

Study documents

Scientific result summary
Available language(s): English

If you wish to request for full study report, please contact - [email protected]

Results overview

Refer to study documents

Recruitment status
Finalized
Actual primary completion date
Not applicable
Actual study completion date
2012-10-08

Plain language summaries

Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.

Additional information about the trial

Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website